読み込み中
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
前日終値
$35.44
+$1.23 · +3.60%
日中の時刻はETです。市場データは遅延する場合があります。
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
日中レンジ
現在 $35.44
52週レンジ
現在 $35.44
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
4
著しい割高
センチメント
59
まちまち
リスク
27
中程度のリスク
モメンタム
71
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
日中レンジ
現在 $35.44
52週レンジ
現在 $35.44
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 826万 USD | 2905.3万 USD | 3271.3万 USD | 3153万 USD | 5528.6万 USD |
| 売上原価 | 128.5万 USD | 91.1万 USD | 159.9万 USD | 303.4万 USD | 896.6万 USD |
| 粗利益 | 697.5万 USD | 2814.2万 USD | 3111.4万 USD | 2849.6万 USD | 4632万 USD |
| 研究開発 | 6.82億 USD | 5.5億 USD | 4.4億 USD | 4.54億 USD | 4.83億 USD |
| 販売・一般管理 | 6.1億 USD | 5.91億 USD | 4.16億 USD | 3.83億 USD | 7.75億 USD |
| 営業費用 | 12.92億 USD | 11.42億 USD | 8.56億 USD | 8.38億 USD | 12.58億 USD |
| 受取利息 | 1.78億 USD | 2.58億 USD | 1.46億 USD | 3218.4万 USD | 36.9万 USD |
| 支払利息 | — | — | 3477.8万 USD | 2796.8万 USD | 704.1万 USD |
| 減価償却費と償却費 | 334.8万 USD | 1407.1万 USD | 2203.6万 USD | 1885.7万 USD | 593.2万 USD |
| 営業利益 | −12.85億 USD | −11.14億 USD | −8.25億 USD | −8.09億 USD | −12.12億 USD |
| 純利益 | −3億 USD | −1.72億 USD | 43.49億 USD | −10.09億 USD | −8.45億 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$46.75
上昇余地（31.91%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI5.55億0.02%2.3兆 USD0.03%$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB4.01億0.21%1853億 USD0.03%$289.48+0.64%
Invesco S&P MidCap Momentum ETFXMMO2.46億3.45%71.38億 USD0.34%$148.79+0.96%
Vanguard Morningstar Small-Cap Growth ETFVBK2.3億0.50%447億 USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF1.81億0.19%954億 USD0.05%$235+0.80%
iShares Biotechnology ETFIBB1.39億1.32%108.2億 USD0.44%$206.49+3.00%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY1.38億0.54%258.17億 USD0.23%$669.87+0.54%
State Street SPDR S&P Biotech ETFXBI1.23億1.24%98.74億 USD0.35%$153.77+3.00%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBInvesco S&P MidCap Momentum ETFXMMOVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBState Street SPDR S&P MIDCAP 400 ETF TrustMDYState Street SPDR S&P Biotech ETFXBIAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
